WallStSmart
AVNS

Avanos Medical Inc

NYSE: AVNS · HEALTHCARE · MEDICAL DEVICES

$24.73
+0.20% today

Updated 2026-06-05

Market cap
$1.17B
P/E ratio
P/S ratio
1.64x
EPS (TTM)
$-1.60
Dividend yield
52W range
$9 – $25
Volume
1.7M

Avanos Medical Inc (AVNS) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item201120122013201420152016201720182019202020212022202320242025
Operating cash flow$139.60M$202.60M$223.80M$147.90M$97.60M$188.80M$144.20M$-145.60M$-74.50M$-2.50M$87.30M$90.90M$32.40M$100.70M$74.70M
Capital expenditures$39.70M$40.80M$49.00M$78.50M$70.40M$29.10M$43.20M$49.10M$50.60M$20.20M$21.00M$19.30M$17.80M$17.80M$31.60M
Depreciation
Stock-based comp$2.60M$5.30M$6.00M$7.90M$14.10M$14.80M$12.60M$10.50M$10.50M$12.10M$13.20M$15.90M$15.80M$13.80M$12.60M
Free cash flow$99.90M$161.80M$174.80M$69.40M$27.20M$159.70M$101.00M$-194.70M$-125.10M$-22.70M$66.30M$71.60M$14.60M$82.90M$43.10M
Investing cash flow
Financing cash flow
Dividends paid$680.00M$0.00$0.00$0.00$5.30M$3.40M$6.20M$1.70M
Share repurchases
Debt repayment
Net change in cash$104.90M$-19.50M$-15.80M$106.00M$164.80M$-181.10M$-96.70M$11.00M$12.20M

Frequently asked questions

What is Avanos Medical Inc's revenue?

Avanos Medical Inc's trailing twelve-month revenue is $715.90M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is AVNS?

In its most recent fiscal year, AVNS ran a gross margin of 49.77%, an operating margin of -8.78%, and a net margin of -9.68%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does AVNS generate?

AVNS produced $43.10M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is AVNS's balance sheet healthy?

AVNS holds $89.80M in cash and equivalents against $90.30M in long-term debt, on $778.20M of shareholder equity. That debt is best read against the cash flow the business throws off each year.